Drug intelligence / Profile preview

NAIN03

Development stage: Preclinical
Lead developer: Hangzhou Nain Biotechnology
Modality: Small Molecules

Overview

NAIN03 is a small molecule inhibitor targeting the insulin-like growth factor 1 receptor (IGF-1R), currently in the IND-enabling phase of development by Hangzhou Nain Biotech. The drug is being investigated for the treatment of solid tumors, specifically glioblastoma and platinum-resistant ovarian cancer. Hangzhou Nain Biotech's development strategy focuses on addressing drug resistance by targeting regulated cell death (RCD) and cancer stem cells (CSC). By inhibiting IGF-1R signaling, NAIN03 aims to disrupt pathways essential for tumor cell proliferation and survival, potentially providing a differentiated therapeutic approach for cancers that have become resistant to standard platinum-based therapies.

Targets

IGF-1R (Insulin-like growth factor 1 receptor)

Beyond the preview

Go deeper on NAIN03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NAIN03.

Explore the full profile